The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer. 

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.